A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT06415669
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastric/Gastroesophageal Junction Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Paclitaxel for injection (albumin-bound) — DRUG
    100 mg/m2, day 1, day 8, every 21 days for a cycle.
  • Adebrelimab — DRUG
    20mg/kg or 1200mg, the first day, every 21 days as a cycle.
  • Apatinib mesylate — DRUG
    250mg once a day for 5 consecutive days and discontinue for 2 days

Study Details

To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.

Key Dates

Start date
May 19, 2024
Status verified
May 2024
Primary completion
May 19, 2026
Completion
May 19, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single arm
    Paclitaxel for injection (albumin-bound) in combination with Apatinib mesylate and adebrelimab

Primary Outcome Measure

Objective response rate（ORR） [ Time Frame: 1 years ]

Central Contacts

Related Studies